Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.
Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million
Forbes - 30 Dec 2017 17:16
Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.
Share this Article
Recommended